BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tovoli F, Negrini G, Benevento F, Faggiano C, Goio E, Granito A. Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. Hepat Oncol 2018;5:HEP01. [PMID: 30302192 DOI: 10.2217/hep-2017-0020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Kounis I, Lewin M, Laurent-Bellue A, Poli E, Coilly A, Duclos-Vallée JC, Guettier C, Adam R, Lerut J, Samuel D, Rosmorduc O. Advanced epithelioid hemangioendothelioma of the liver: could lenvatinib offer a bridge treatment to liver transplantation? Ther Adv Med Oncol 2022;14:17588359221086909. [PMID: 35340695 DOI: 10.1177/17588359221086909] [Reference Citation Analysis]
2 Kim HD, Bang Y, Lee MA, Kim JW, Kim JH, Chon HJ, Kang B, Kang MJ, Kim I, Cheon J, Hwang JE, Kang JH, Byeon S, Hong JY, Ryoo BY, Lim HY, Yoo C. Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. Liver Int. 2020;40:2544-2552. [PMID: 32563213 DOI: 10.1111/liv.14573] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
3 Huot JR, Essex AL, Gutierrez M, Barreto R, Wang M, Waning DL, Plotkin LI, Bonetto A. Chronic Treatment with Multi-Kinase Inhibitors Causes Differential Toxicities on Skeletal and Cardiac Muscles. Cancers (Basel) 2019;11:E571. [PMID: 31018508 DOI: 10.3390/cancers11040571] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
4 Bort A, Sánchez BG, Mateos-Gómez PA, Vara-Ciruelos D, Rodríguez-Henche N, Díaz-Laviada I. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib. Mol Oncol 2019;13:1311-31. [PMID: 30959553 DOI: 10.1002/1878-0261.12488] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
5 Martin SP, Wang XW. The evolving landscape of precision medicine in primary liver cancer. Hepat Oncol 2019;6:HEP12. [PMID: 31205678 DOI: 10.2217/hep-2019-0004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
6 Alqahtani A, Khan Z, Alloghbi A, Said Ahmed TS, Ashraf M, Hammouda DM. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. Medicina (Kaunas) 2019;55:E526. [PMID: 31450841 DOI: 10.3390/medicina55090526] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
7 Liu Z, Li X, He X, Xu Y, Wang X. Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report. BMC Cancer. 2019;19:1062. [PMID: 31703571 DOI: 10.1186/s12885-019-6287-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 Leoni S, Sansone V, Lorenzo S, Ielasi L, Tovoli F, Renzulli M, Golfieri R, Spinelli D, Piscaglia F. Treatment of Combined Hepatocellular and Cholangiocarcinoma. Cancers (Basel) 2020;12:E794. [PMID: 32224916 DOI: 10.3390/cancers12040794] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
9 Lin HS, Huang YL, Wang YS, Hsiao E, Hsu TA, Shiao HY, Jiaang WT, Sampurna BP, Lin KH, Wu MS, Lai GM, Yuh CH. Identification of Novel Anti-Liver Cancer Small Molecules with Better Therapeutic Index than Sorafenib via Zebrafish Drug Screening Platform. Cancers (Basel) 2019;11:E739. [PMID: 31141996 DOI: 10.3390/cancers11060739] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
10 Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. Cancers (Basel). 2019;11. [PMID: 31216701 DOI: 10.3390/cancers11060841] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
11 Tovoli F, De Lorenzo S, Trevisani F. Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now? Vaccines (Basel) 2020;8:E578. [PMID: 33023131 DOI: 10.3390/vaccines8040578] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
12 Xing J, Tian Y, Ji W, Wang X. Comprehensive evaluation of SPATS2 expression and its prognostic potential in liver cancer. Medicine (Baltimore) 2020;99:e19230. [PMID: 32118724 DOI: 10.1097/MD.0000000000019230] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
13 Li Z, Li H, Zhao ZB, Zhu W, Feng PP, Zhu XW, Gong JP. SIRT4 silencing in tumor-associated macrophages promotes HCC development via PPARδ signalling-mediated alternative activation of macrophages. J Exp Clin Cancer Res 2019;38:469. [PMID: 31744516 DOI: 10.1186/s13046-019-1456-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
14 Lünse S, Heidecke C, Partecke LI; Department of General Surgery, Visceral, Thoracic and Vascular Surgery, Universitätsmedizin Greifswald, Greifswald, Germany, Department of General Surgery, Visceral, Thoracic and Vascular Surgery, Universitätsmedizin Greifswald, Greifswald, Germany, Department of General, Visceral and Thoracic Surgery, Helios Klinikum Schleswig, Schleswig, Germany. Current Topics and Perspectives in Surgical Management of Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 111-25. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch6] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Cao X, Zhang G, Li T, Zhou C, Bai L, Zhao J, Tursun T. LINC00657 knockdown suppresses hepatocellular carcinoma progression by sponging miR-424 to regulate PD-L1 expression. Genes Genomics 2020;42:1361-8. [PMID: 32996041 DOI: 10.1007/s13258-020-01001-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Goio E, Ielasi L, Benevento F, Renzulli M, Tovoli F. Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery. Hepat Oncol 2020;7:HEP24. [PMID: 32774834 DOI: 10.2217/hep-2020-0014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Zhu Q, Luo M, Zhou C, Chen Z, Huang W, Huang J, Zhao S, Yu X. [Effect of danusertib on cell cycle, apoptosis and autophagy of hepatocellular carcinoma HepG2 cells in vitro]. Nan Fang Yi Ke Da Xue Xue Bao 2018;38:1476-84. [PMID: 30613017 DOI: 10.12122/j.issn.1673-4254.2018.12.13] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
18 Qin S, Finn RS, Kudo M, Meyer T, Vogel A, Ducreux M, Macarulla TM, Tomasello G, Boisserie F, Hou J, Li X, Song J, Zhu AX. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncol 2019;15:1811-22. [PMID: 30969136 DOI: 10.2217/fon-2019-0097] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
19 Elkhenany H, Shekshek A, Abdel-Daim M, El-Badri N. Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives. Adv Exp Med Biol 2020;1237:97-119. [PMID: 31728916 DOI: 10.1007/5584_2019_441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
20 Huynh H, Prawira A, Le TBU, Vu TC, Hao HX, Huang A, Wang Y, Porta DG. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma. Exp Mol Med 2020;52:1857-68. [PMID: 33235319 DOI: 10.1038/s12276-020-00524-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Herrero A, Knetemann E, Mannaerts I. Review: Challenges of In Vitro CAF Modelling in Liver Cancers. Cancers (Basel) 2021;13:5914. [PMID: 34885024 DOI: 10.3390/cancers13235914] [Reference Citation Analysis]
22 Yabuta S, Shidoji Y. Cytoplasmic translocation of nuclear LSD1 (KDM1A) in human hepatoma cells is induced by its inhibitors. Hepat Oncol 2019;6:HEP13. [PMID: 31205679 DOI: 10.2217/hep-2018-0008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]